Global pharmaceutical giant Eli Lilly and Company on July 16 announced a $3.8 billion acquisition agreement with AtaiBeckley, a New York City-based clinical-stage biopharmaceutical firm known for its innovative therapeutics in treating mental health conditions.
AtaiBeckley has been developing a series of rapid-acting neuroplastogens, a class of drugs used to treat central nervous system disorders by helping brain cells to reorganize neural connections. These developments include multiple clinical-stage programs and a pipeline of next-generation compounds.
The company’s leading product, BPL-003, also known as mebufotenin benzoate, is being developed for patients with treatment-resistant depression. The medication is a synthetic form of 5-MeO-DMT, a psychedelic drug that is administered through the nasal passages.
According to Lilly’s announcement, the U.S. Food and Drug Administration has already granted BPL-003 a “Breakthrough Therapy Designation,” and Phase 3 activities have commenced.
Under the terms of the agreement, Lilly will acquire all outstanding shares of AtaiBeckley common stock for $6.75 per share in cash upon closing. In addition, it will pay up to $2.50 per share in the form of a Contingent Value Right (CVR), entitling the holder to additional cash payments upon achievement of certain milestones.
The upfront cash represents an aggregate equity value of nearly $2.8 billion, and the CVR represents an additional potential aggregate equity value of close to $1 billion.
The transaction is not subject to any financing condition and is expected to close in the third quarter, subject to approval by AtaiBeckley stockholders and satisfaction of other customary closing conditions, including regulatory approvals.
William Soliman, founder and CEO of the Accreditation Council for Medical Affairs (ACMA), said that the merger marks a significant shift in Lilly’s core pharmaceutical development efforts geared toward the treatment of diabetes, obesity, and cancer.
“Lilly is using the financial strength generated by its obesity and diabetes franchises to diversify into neuroscience and other high-need therapeutic areas,” he said in a note emailed to The Epoch Times.
“The opportunity is substantial because treatment-resistant depression affects patients who have already failed multiple conventional therapies.”
Soliman added that the acquisition represents support for psychedelic-inspired drug development as a part of mainstream pharmaceutical research and development.
“When a company of Lilly’s scale commits billions of dollars, it signals that rapid-acting psychiatric therapies are moving from speculative science toward mainstream pharmaceutical development,” he said.
Commercial success of the new medication, he said, will depend on whether the therapies can be delivered without requiring lengthy and expensive treatment center visits.
Soliman also said the deal shows that large pharmaceutical companies like Lilly are investing in innovation to transform effective but burdensome therapies into more patient-friendly formulations, and are using revenues to acquire the next generation of growth.
“Lilly is making a multibillion-dollar bet on an entirely new treatment paradigm in mental health,” he said.
Lilly has also been expanding into other areas through acquisitions. At the end of May, the company announced deals to acquire three vaccine-focused biotech companies for up to $3.83 billion, broadening its infectious disease portfolio.
AtaiBeckley was founded in 2025 following the merger of Atai Life Sciences and Beckley Psytech.
Indianapolis-based Lilly has been developing medicines for over 150 years, including treatments for diabetes and obesity, as well as cancer.
